This article is more than 5 years old. Information may no longer be current.

Sanofi releases generic version of Arava tablets for patients with RA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Sanofi announced it has released an authorized generic version of Arava for the treatment of patients with rheumatoid arthritis, according to a company press release.

Winthrop, Sanofi’s U.S. generic drugs division, will produce the generic Arava (leflunomide, Sanofi) for which Sanofi holds the original patent.

“The Arava authorized generic assures patients that they receive the same quality treatment of the original drug,” Cary Yonce, PharmD, vice president, General Therapeutics and Life Cycle Management at Sanofi, said in a press release. “We are committed to making authorized generics like Arava available and affordable to patients who need them.”

According to the release, its new version of leflunomide has identical chemical makeup to Arava, but inert ingredients may vary. Leflunomide, first approved in 1998 for the treatment of rheumatoid arthritis (RA), can be prescribed as monotherapy or in combination with other disease-modifying anti-rheumatic drugs (DMARDs) or biological therapies, according to the company.

Reference : http://www.sanofi.us.